Hyperion Therapeutics (FRA:0HY) COGS-to-Revenue : 0.12 (As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics COGS-to-Revenue?

Hyperion Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2015 was €3.5 Mil. Its Revenue for the three months ended in Mar. 2015 was €28.8 Mil.

Hyperion Therapeutics's COGS to Revenue for the three months ended in Mar. 2015 was 0.12.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hyperion Therapeutics's Gross Margin % for the three months ended in Mar. 2015 was 87.71%.

Hyperion Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Hyperion Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics COGS-to-Revenue Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

COGS-to-Revenue

0.16

0.12

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
COGS-to-Revenue	Get a 7-Day Free Trial													0.12	0.12	0.12	0.12	0.12

Hyperion Therapeutics COGS-to-Revenue Calculation

Hyperion Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2014 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.133	/	92.117
	=	0.12

Hyperion Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2015 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.541	/	28.822
	=	0.12

Hyperion Therapeutics (FRA:0HY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hyperion Therapeutics's Gross Margin % for the three months ended in Mar. 2015 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.541 / 28.822
	=	87.71 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hyperion Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics Headlines

No Headlines